Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors

Inclusion Criteria: * Patient must be 18 years or older with confirmed diagnosis of a solid tumor for which pemetrexed and cisplatin is acceptable treatment and have received no more than 2 prior systemic therapies * Has at least 1 measurable lesion * Has adequate blood, liver, and kidney functions * Has not received any chemotherapy for at least 4 weeks prior to entry in this study * Agrees to take adequate measures to prevent pregnancy as outlined in the protocol Exclusion Criteria: * Patient has been treated with other investigational agents with a similar anti-tumor mechanism * Patient from Cohorts A and B has received pemetrexed or cisplatin within the past 6 months and from Cohorts C and D have received pemetrexed within the past 6 months * Patient from Cohorts A and B has preexisting Grade 2 or higher neuropathy and from Cohorts C and D have Grade 3 or higher neuropathy * Patient has active infection or had received IV (intravenous) antibiotic, antiviral, or antifungal medications within 2 weeks of the start of study drugs * Patient has HIV, hepatitis B or hepatitis C infection * Patient is pregnant or breast feeding * Patient has allergy to any component of the study drugs * Patient has history of GI (gastrointestinal) surgery or conditions